

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (Currently Amended) A method for reduction of adhesion formation wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment, and wherein the administration of the substance that inhibits a pro-inflammatory cytokine causes a reduction of adhesion formation.

2. (Original) The method of claim 1, wherein said pro-inflammatory cytokine is selected from the group consisting of TNF, IL-1, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, GM-CSF, M-CSF, MCP-1, MIP-1, RANTES, ENA-78, OSM, FGF, PDGF, and VEGF.

3. (Original) The method of claim 1, wherein said pro-inflammatory cytokine is selected from the group consisting of TNF and IL-1.

4. (Original) The method of claim 1, for treatment of post-traumatic tissue injury.

5. (Original) The method of claim 4, wherein said post-traumatic tissue injury is caused by surgery.

6. (Original) The method of claim 1, for treatment of a thermic injury.

7. (Original) The method of claim 1, for treatment of a pathological condition with scar formation.

8. (Original) The method of claim 7, wherein said pathological condition with scar formation is caused by a vascular disease selected from the group consisting of bleeding and infarct.

9. (Original) The method of claim 7, wherein said pathological condition with scar formation is caused by a toxic influence.

10. (Original) The method of claim 7, wherein said pathological condition with scar formation is caused by cystic fibrosis.

11. - 22. (Canceled).

23. (Original) The method of claim 1, wherein said substance is lactoferrin or a peptide derived from lactoferrin.

24. (Original) The method of claim 1, wherein said substance is locally administered.

25. (Original) The method of claim 1, wherein said substance is systemically administered.